A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder.
This research study is looking at a new medicine called BP1.4979 for treating binge eating disorder. Participants will either receive the new medicine or a matching dummy pill (placebo), without knowing which one they have. This helps us fairly compare the medicine's effects. The main goal is to see if BP1.4979 reduces the number of binge eating episodes people experience each week, based on their self-reported diaries. We will compare binge eating episodes from before starting treatment to the end of the study. We will also check other things like how it affects food cravings and overall well-being. This is an early-stage study, meaning we are still exploring if the treatment works and is safe for people with binge eating disorder.
At a glance
What is this study about?
This study is an important step in understanding and potentially finding new treatments for binge eating disorder. We're testing a new medicine, BP1.4979, to see if it can help reduce binge eating episodes. Binge eating disorder involves regularly eating large amounts of food, often very quickly and feeling a loss of control, followed by feelings of guilt or shame. It's a serious condition that can affect many aspects of a person's life.
In this study, some people will receive the new medicine, while others will receive a 'dummy' pill, called a placebo. This is a common practice in medical research. Neither you nor your doctor will know which you are receiving. This method ensures that any improvements seen are genuinely due to the medicine and not just other factors. This study is in an early phase, meaning we are exploring if the treatment works and is safe before moving to larger studies.
The main thing we want to find out is whether taking BP1.4979 reduces the number of times a person binges each week. Participants will keep a diary to track their binge eating episodes. We'll compare the number of episodes from before the study started to the end of the treatment period to see if there's a difference. We'll also look at other aspects like changes in food cravings, how people generally feel, and the number of days someone has a binge eating episode.
Key takeaways
- A new medicine, BP1.4979, is being tested for binge eating disorder.
- The study compares the new medicine to a dummy pill (placebo).
- It aims to see if the medicine reduces binge eating episodes.
- Only adult women are eligible to participate.
- The study lasts for eight weeks and involves regular clinic visits and diaries.
Who may be eligible?
This study is specifically looking for adult women who have been diagnosed with binge eating disorder.
To be considered for the study, you must be at least 18 years old. There is no upper age limit for participation, meaning women of any adult age can take part as long as they meet the other study requirements.
More detailed health information will be needed to decide if this study is suitable for you, but these are the main starting points for eligibility.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you a woman?
- Have you been diagnosed with binge eating disorder?
- Are you able to attend appointments regularly for 8 weeks?
What does participation involve?
If you decide to take part in this study, you will be in the study for a total of eight weeks. During this time, you will take either the study medicine or a dummy pill each day. You won't know which one you are taking.
You will need to attend several appointments at the clinic over these eight weeks. During these visits, the study team will check your health, ask you questions about your eating habits, and collect information through questionnaires. You will also be asked to keep a weekly diary of any binge eating episodes you experience. Some participants might also wear a small device that monitors blood sugar levels to give us more information about eating patterns.
There will be specific times for these visits, including a check-up before you start treatment, and regular visits throughout the eight weeks to monitor your progress and well-being. The study team will explain everything to you in detail before you make a decision.
Potential risks and benefits
Locations (2)
- —UnverifiedFrance
- —UnverifiedSpain
Common questions
What is BP1.4979?
BP1.4979 is a new investigational medicine being tested to see if it can help people with binge eating disorder.
What does 'double-blind' mean?
It means neither you nor your study doctor will know if you are taking the new medicine or the dummy pill (placebo) during the study.
What is a 'placebo'?
A placebo is an inactive pill that looks exactly like the study medicine but doesn't contain any active ingredients. It helps us see if the new medicine really works.
How long will I be in the study?
The study will last for a total of eight weeks.
Can men join this study?
No, this particular study is only open to adult women.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.